03 Jun 2024
07:30 CEST |
TRANSGENE |
Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
|
20103010 Biotechnology |
Other subject |
03 Jun 2024
07:30 CEST |
TRANSGENE |
Transgene – Premier patient inclus dans la partie Phase II de l’étude randomisée de Phase I/II de son actif phare TG4050, un vaccin thérapeutique individualisé évalué dans les cancers de la tête et du cou
|
20103010 Biotechnology |
Other subject |
15 May 2024
17:45 CEST |
TRANSGENE |
Assemblée Générale Mixte de Transgene du 15 mai 2024
|
20103010 Biotechnology |
General meeting / Board Meeting |
15 May 2024
17:45 CEST |
TRANSGENE |
Transgene’s Combined General Meeting of May 15, 2024
|
20103010 Biotechnology |
General meeting / Board Meeting |
14 May 2024
17:45 CEST |
TRANSGENE |
Transgene fait le point sur ses activités et sa situation financière au premier trimestre 2024
|
20103010 Biotechnology |
Sales |
14 May 2024
17:45 CEST |
TRANSGENE |
Transgene provides business and financial update for Q1 2024
|
20103010 Biotechnology |
Sales |
24 Apr 2024
17:45 CEST |
TRANSGENE |
Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai 2024
|
20103010 Biotechnology |
General meeting / Board Meeting |
24 Apr 2024
17:45 CEST |
TRANSGENE |
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024
|
20103010 Biotechnology |
General meeting / Board Meeting |
11 Apr 2024
19:05 CEST |
TRANSGENE |
Document d'enregistrement Universel 2023
|
20103010 Biotechnology |
Income |
11 Apr 2024
17:45 CEST |
TRANSGENE |
Availability of Transgene's 2023 Universal Registration Document
|
20103010 Biotechnology |
Other subject |
11 Apr 2024
17:45 CEST |
TRANSGENE |
MIse à disposition du document d'enregistrement universel 2023 de Transgene
|
20103010 Biotechnology |
Other subject |
09 Apr 2024
17:45 CEST |
TRANSGENE |
Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024
|
20103010 Biotechnology |
New |
09 Apr 2024
17:45 CEST |
TRANSGENE |
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
|
20103010 Biotechnology |
New |
27 Mar 2024
17:45 CET |
TRANSGENE |
Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025
|
20103010 Biotechnology |
Income |
27 Mar 2024
17:45 CET |
TRANSGENE |
Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle Schwoerer Comme Directrice des Ressources Humaines
|
20103010 Biotechnology |
Journal / appointments |
27 Mar 2024
17:45 CET |
TRANSGENE |
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
|
20103010 Biotechnology |
Income |
27 Mar 2024
17:45 CET |
TRANSGENE |
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
|
20103010 Biotechnology |
Journal / appointments |
18 Mar 2024
17:45 CET |
TRANSGENE |
Transgene Announces Upcoming Investor Meetings
|
20103010 Biotechnology |
Meetings / events |
18 Mar 2024
17:45 CET |
TRANSGENE |
Transgene annonce ses prochaines rencontres avec les investisseurs
|
20103010 Biotechnology |
Meetings / events |
06 Mar 2024
07:30 CET |
TRANSGENE |
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
|
20103010 Biotechnology |
Other subject |
06 Mar 2024
07:30 CET |
TRANSGENE |
Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à l’AACR 2024
|
20103010 Biotechnology |
Other subject |
05 Mar 2024
07:30 CET |
TRANSGENE |
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
|
20103010 Biotechnology |
Alliances and agreements |
05 Mar 2024
07:30 CET |
TRANSGENE |
Transgene, NEC et BostonGene étendent leur collaboration dans le cadre de l’essai clinique de Phase I/II du vaccin individualisé TG4050
|
20103010 Biotechnology |
Alliances and agreements |
22 Jan 2024
17:45 CET |
TRANSGENE |
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
|
20103010 Biotechnology |
Journal / appointments |
22 Jan 2024
17:45 CET |
TRANSGENE |
Transgene annonce la nomination de James Wentworth comme Directeur du Business Development
|
20103010 Biotechnology |
Journal / appointments |
22 Jan 2024
08:00 CET |
TRANSGENE |
Transgene Announces Financial Calendar for 2024
|
20103010 Biotechnology |
Other subject |
22 Jan 2024
08:00 CET |
TRANSGENE |
Transgene présente son calendrier de communication financière pour 2024
|
20103010 Biotechnology |
Other subject |
08 Jan 2024
17:45 CET |
TRANSGENE |
Transgene et NEC étendent leur collaboration et poursuivent ensemble le développement clinique de TG4050, un vaccin thérapeutique individualisé contre le cancer
|
20103010 Biotechnology |
Alliances and agreements |
08 Jan 2024
17:45 CET |
TRANSGENE |
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
|
20103010 Biotechnology |
Alliances and agreements |
04 Jan 2024
17:45 CET |
TRANSGENE |
Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 31 décembre 2023
|
20103010 Biotechnology |
Share history |
04 Jan 2024
17:45 CET |
TRANSGENE |
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023
|
20103010 Biotechnology |
Share history |
21 Dec 2023
17:45 CET |
TRANSGENE |
Transgene Announces Upcoming Investor Meetings
|
20103010 Biotechnology |
Meetings / events |
21 Dec 2023
17:45 CET |
TRANSGENE |
Transgene annonce ses prochaines rencontres avec les investisseurs
|
20103010 Biotechnology |
Meetings / events |
05 Dec 2023
17:45 CET |
TRANSGENE |
Transgene renforce son équipe de direction pour accélérer sa stratégie de croissance
|
20103010 Biotechnology |
Journal / appointments |
05 Dec 2023
17:45 CET |
TRANSGENE |
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
|
20103010 Biotechnology |
Journal / appointments |
07 Nov 2023
17:45 CET |
TRANSGENE |
Transgene fait le point sur ses activités et sa situation financière au troisième trimestre 2023
|
20103010 Biotechnology |
Income |
07 Nov 2023
17:45 CET |
TRANSGENE |
Transgene Reports Business Update and Q3 2023 Financial Position
|
20103010 Biotechnology |
Income |
10 Oct 2023
07:30 CEST |
TRANSGENE |
Transgene et BioInvent – Un premier patient traité dans la partie B de l’essai de Phase I évaluant le virus oncolytique BT-001 en combinaison avec KEYTRUDA® (pembrolizumab)
|
20103010 Biotechnology |
New |
10 Oct 2023
07:30 CEST |
TRANSGENE |
Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab)
|
20103010 Biotechnology |
New |
20 Sep 2023
17:45 CEST |
TRANSGENE |
Transgene fait progresser son portefeuille d’immunothérapies innovantes et étend sa visibilité financière jusqu’à fin 2024
|
20103010 Biotechnology |
Other financial transaction |
20 Sep 2023
17:45 CEST |
TRANSGENE |
Availability of Transgene’s Half-Year Financial Report as of June 30, 2023
|
20103010 Biotechnology |
Income |
20 Sep 2023
17:45 CEST |
TRANSGENE |
Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024
|
20103010 Biotechnology |
Other financial transaction |
20 Sep 2023
17:45 CEST |
TRANSGENE |
Transgene : Mise à disposition du Rapport Financier Semestriel au 30 juin 2023
|
20103010 Biotechnology |
Income |
14 Sep 2023
17:45 CEST |
TRANSGENE |
Transgene Announces Upcoming Investor Meetings
|
20103010 Biotechnology |
Meetings / events |
14 Sep 2023
17:45 CEST |
TRANSGENE |
Transgene annonce ses prochaines rencontres avec les investisseurs
|
20103010 Biotechnology |
Meetings / events |
17 Jul 2023
17:45 CEST |
TRANSGENE |
Transgene encaisse 15,3 millions de dollars grâce à la cession d’actifs financiers destinés à la vente
|
20103010 Biotechnology |
Other financial transaction |
17 Jul 2023
17:45 CEST |
TRANSGENE |
Transgene Receives $15.3 Million from the Sale of Securities Held for Sale
|
20103010 Biotechnology |
Other financial transaction |
12 Jul 2023
18:00 CEST |
TRANSGENE |
Transgene: Balance Sheet of the Liquidity Contract with Natixis Oddo BHF SCA as of June 30, 2023
|
20103010 Biotechnology |
Other financial transaction |
12 Jul 2023
18:00 CEST |
TRANSGENE |
Transgene : Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 30 juin 2023
|
20103010 Biotechnology |
Other financial transaction |
06 Jun 2023
07:30 CEST |
TRANSGENE |
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
|
20103010 Biotechnology |
Meetings / events |